Milestone Pharmaceuticals Inc. Logo

Milestone Pharmaceuticals Inc.

Developing a self-administered nasal spray for at-home treatment of acute cardiac events.

MIST | US

Overview

Corporate Details

ISIN(s):
USU6005B1045 (+1 more)
LEI:
549300P43IPGW3Q3Y026
Country:
United States of America
Address:
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, 07039 MONTREAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for episodic cardiovascular conditions. The company's lead investigational product is etripamil, a proprietary, novel calcium channel blocker delivered as a self-administered nasal spray. This therapy is designed for the rapid termination of paroxysmal supraventricular tachycardia (PSVT) episodes in an at-home setting, addressing a significant unmet need for treatment outside of the emergency department. Milestone is also exploring etripamil's potential for other conditions, such as atrial fibrillation with rapid ventricular rate (AFib-RVR), to provide patients with control over acute cardiac events.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Milestone Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Milestone Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Milestone Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea
456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden
GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium
GLPG
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland
GALD
GALECTIN THERAPEUTICS INC Logo
Developing galectin-3 inhibitors for MASH cirrhosis, fibrosis, and cancer.
United States of America
GALT
Galecto, Inc. Logo
Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.
United States of America
GLTO
Galmed Pharmaceuticals Ltd. Logo
Develops oral therapeutics for liver, metabolic, and inflammatory diseases like NASH.
United States of America
GLMD
GC CELL CORPORATION Logo
Biotech firm offering cell/gene therapy CDMO services and developing immune cell cancer therapies.
South Korea
144510
Gelteq Ltd Logo
Ingestible gel platform for enhanced oral delivery of drugs & nutrients for human & animal health.
United States of America
GELS
GemVax & KAEL Co.,Ltd. Logo
Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.
South Korea
082270

Talk to a Data Expert

Have a question? We'll get back to you promptly.